Research
Hormonal
Type 2 diabetes mellitus (T2DM) and insulin resistance are significant independent risk factors for the progression of NAFLD to NASH, fibrosis, and cirrhosis, and are associated with increased mortality.
If you have NAFLD and Type 2 Diabetes, managing your blood sugar and insulin resistance is critical to preventing liver damage. T2DM is an independent risk factor for progression to cirrhosis and liver-related mortality.
StrongSupportsVERY_HIGH confidence
T2DM and insulin resistance promote lipolysis of the adipose tissue leading to release of free fatty acids and their deposition in the liver leading to steatosis. T2DM is a significant risk factor to cause progressive NASH, fibrosis, cirrhosis and an independent risk factor of mortality in addition to liver-related mortality.
Why this rating
Cited as a significant risk factor with clear mechanistic and outcome data in a comprehensive review.
Source
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease
Brandon J. Perumpail et al. · World Journal of Gastroenterology · 2017
DOI 10.3748/wjg.v23.i47.8263
narrative_reviewCited 770×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Consumption of sugar-sweetened beverages containing fructose or high fructose corn syrup promotes de novo lipogenesis and triggers inflammatory responses leading to hepatocyte apoptosis, directly contributing to the development of nonalcoholic fatty liver disease (NAFLD).Good
- Visceral adiposity is an independent risk factor for developing NAFLD and significant fibrosis, whereas subcutaneous adiposity may be associated with regression of the disease.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →